Humanized Mouse as a Tool to Predict Immunotoxicity of Human Biologics
Author(s)
Yong, Kylie Su Mei; Her, Zhisheng; Tan, Sue Yee; Tan, Wilson Wei Sheng; Liu, Min; Lai, Fritz; Heng, Shi Min; Fan, Yong; Chang, Kenneth Tou En; Wang, Cheng-I; Chan, Jerry Kok Yen; Chen, Jianzhu; Chen, Qingfeng; ... Show more Show less
DownloadPublished version (1.910Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
© Copyright © 2020 Yong, Her, Tan, Tan, Liu, Lai, Heng, Fan, Chang, Wang, Chan, Chen and Chen. Advancements in science enable researchers to constantly innovate and create novel biologics. However, the use of non-human animal models during the development of biologics impedes identification of precise in vivo interactions between the human immune system and treatments. Due to lack of this understanding, adverse effects are frequently observed in healthy volunteers and patients exposed to potential biologics during clinical trials. In this study, we evaluated and compared the effects of known immunotoxic biologics, Proleukin®/IL-2 and OKT3 in humanized mice (reconstituted with human fetal cells) to published clinical outcomes. We demonstrated that humanized mice were able to recapitulate in vivo pathological changes and human-specific immune responses, such as elevated cytokine levels and modulated lymphocytes and myeloid subsets. Given the high similarities of immunological side effects observed between humanized mice and clinical studies, this model could be used to assess immunotoxicity of biologics at a pre-clinical stage, without placing research participants and/or patients at risk.
Date issued
2020-10Department
Singapore-MIT Alliance in Research and Technology (SMART); Koch Institute for Integrative Cancer Research at MIT; Massachusetts Institute of Technology. Department of BiologyJournal
Frontiers in Immunology
Publisher
Frontiers Media SA
ISSN
1664-3224